Transaction · 0001213900-26-110340

David Matthew T

David Matthew T, CFO, reported a transaction classified as grant at Actinium Pharmaceuticals, Inc. involving 250000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 250000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACFO
ATNMActinium Pharmaceuticals, Inc.
Trade date
Oct 14, 2026
Filing date
Oct 16, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded250k$0.00 per share
Holdings after250kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ATNM price since this filing

Daily closing prices, with the filing date and available return windows
ATNM · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +9.4%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001213900-26-110340
Stock Option (right to purchase)
Transaction date
Oct 14, 2026
Filed Oct 16, 2026, 09:11 PM · 2d delay
Shares
250,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
250,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    On October 14, 2026 (the "Grant Date"), Mr. David was granted two hundred fifty thousand (250,000) Restricted Stock Units ("RSUs") under the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement A…

  2. F2

    On the Grant Date, Mr. David was granted the option to purchase 250,000 shares of common stock (the "Option Grant") of Actinium Pharmaceuticals, Inc. (the "Issuer") under the Inducement Plan.

  3. F3

    Twenty-eight percent (28%) of the Option Grant shall vest twelve (12) months after the Grant Date and two percent (2%) of the Option Grant shall vest each month thereafter, subject to Mr. David's cont…

Original filing · 0001213900-26-110340
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ATNM